OCEA Profile
Ocean Biomedical, Inc., based in Providence, Rhode Island, is an innovative biopharmaceutical company dedicated to discovering and developing cutting-edge therapeutic products across various medical fields. Founded in 2019, Ocean Biomedical focuses on advancing treatments in oncology, fibrosis, infectious diseases, and inflammation. The company is at the forefront of developing novel therapies using a range of platforms and approaches, including humanized monoclonal antibodies and small molecules.
In the oncology sector, Ocean Biomedical is advancing several promising product candidates. The company is developing both mono-specific and bi-specific humanized monoclonal antibodies aimed at targeting Chi3l1. These antibodies are intended for the treatment of aggressive cancers such as non-small cell lung cancer and glioblastoma multiforme. Additionally, Ocean Biomedical is working on a small molecule product candidate designed to inhibit Chit1, targeting Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome, which are challenging and rare conditions with significant unmet medical needs.
The company is also leveraging its proprietary WPDS platform to address infectious diseases, particularly malaria. This platform includes the development of a malaria vaccine candidate, which aims to provide a crucial tool in preventing this widespread disease. Furthermore, Ocean Biomedical is working on a humanized monoclonal antibody therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP), a critical antigen in malaria treatment. In addition to the antibody-based approach, the company is developing a small molecule therapeutic targeting PfGARP and another product candidate focused on treating COVID-19 in hospitalized patients, reflecting Ocean Biomedical's commitment to addressing both current and emerging global health challenges.
Ocean Biomedical’s diverse pipeline and innovative approaches underscore its role as a key player in the biopharmaceutical industry. By integrating advanced technologies and novel therapeutic strategies, the company aims to make significant contributions to the treatment of serious and underserved medical conditions. Its research and development efforts are poised to deliver transformative solutions and enhance patient outcomes across multiple therapeutic areas.
|
